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ABSTRACT
Activated platelets play a crucial role in the
pathogenesis of atherothrombotic disease and
its complications. Even under treatment of
antiplatelet drugs, such as acetylsalicylic acid
and P2Y12 antagonists, morbidity and mortality
rates of thromboembolic complications remain
high. Hence, the therapeutic inhibition of
protease-activated receptor (PAR)-1, which is
activated by thrombin, is a novel promising
approach in antiplatelet therapy. Recent data
suggest that PAR-1 is mainly involved in
pathological thrombus formation, but not in
physiological hemostasis. Therefore, PAR-1
inhibition offers the possibility to reduce
atherothrombotic events without increasing
bleeding risk. So far, two emerging PAR-1
antagonists have been tested in clinical
trials: vorapaxar (SCH530349; Merck & Co.,
Whitehouse Station, NJ, USA) and atopaxar
(E5555; Eisai, Tokyo, Japan). Although in TRA-
CER vorapaxar showed an unfavorable profile
for patients with acute coronary syndrome in
addition to standard therapy, it revealed
promising results for patients with prior
myocardial infarction in TRA 2P-TIMI50.
Depending on the status of clinical approval,
vorapaxar might be an option for patients with
peripheral arterial disease to reduce limb
ischemia. The second PAR-I antagonist,
atopaxar, tended towards reducing major
cardiovascular adverse events in acute coronary
syndrome patients in a phase II trial. However,
although statistically not significant, bleeding
events were numerically increased in atopaxar-
treated patients compared with placebo.
Furthermore, liver enzymes were elevated and
the relative corrected QT interval was prolonged
in atopaxar-treated patients. Currently, the
development of atopaxar by Eisai is
discontinued. The future of this novel class of
antithrombotic drugs will depend on the
identification of patient groups in which the
risk–benefit ratio is favorable.
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INTRODUCTION
Worldwide, clinical manifestations of
cardiovascular diseases, such as acute coronary
syndrome (ACS), coronary artery disease (CAD),
and ischemic stroke, are among the leading
causes of death [1]. The underlying pathogenetic
mechanisms of ACS are multifactorial but finally
lead via platelet activation to intravascular clot
formation and vessel occlusion with ischemia of
the downstream located tissue [2].
Platelet activation, which commonly occurs
when platelets are exposed to subendothelial
structures such as fibrinogen, is a physiological
process of primary hemostasis. Activation of the
glycoprotein (GP)Ib/V/IX, which is expressed
on the surface of platelets, mediates the initial
tethering of platelets to the vessel wall. Binding
of the platelets to von Willebrand factor,
which is exposed in subendothelial tissues
following vascular injury, triggers an
interaction between GPVI and collagen.
Autocrine and paracrine stimulation of platelet
receptors by potent platelet-aggregating
agonists and vasoconstrictors, such as
thromboxane A2 (TXA2), platelet-activating
factor, and adenosine diphosphate (ADP), lead
to activation of an integrin called GPIIb/IIIa,
which is also expressed on the platelet surface.
As a result, the soluble plasma coagulation
factor, fibrinogen, binds to this receptor and
mediates platelet-to-platelet aggregation, and
consequently, a primary platelet plug, or
thrombus, at the site of injury is formed.
Another important platelet agonist is
thrombin. It is generated in the coagulation
cascade, a pathway of secondary hemostasis,
which is activated simultaneously with primary
hemostasis. A main function of thrombin is the
conversion of fibrinogen to the insoluble
protein fibrin, the major stabilizing
component of the thrombus. Physiologic
activation of these pathways contributes to the
prevention and control of bleeding events.
Notably, pathological platelet activation
causes thrombus formation in conditions
other than after vascular injury, such as after
plaque rupture [3]. The stationary or traveling
thrombus (embolism) may cause the occlusion
of arteries and subsequent ischemic cell death
[3] resulting in ACS or a myocardial infarction
(MI). Invasive treatment options in ACS include
coronary revascularization with percutaneous
coronary intervention (PCI) or in rare cases
acute coronary artery bypass graft surgery.
CURRENT ANTIPLATELET THERAPY
Enhanced platelet activation can be found in
ACS patients and often leads to thrombus
formation and cardiac ischemia. Hence,
international cardiac societies recommend the
use of antiplatelet drugs, e.g., acetylsalicylic
acid (ASA) and P2Y12 antagonists for these
patients in order to reduce ischemic
complications [4–6].
ASA is an irreversible cyclooxygenase-1
inhibitor, and thereby reduces intraplatelet
production of prothrombotic TXA2 with
consecutive inhibited platelet aggregation.
P2Y12 antagonists (clopidogrel, prasugrel, and
ticagrelor) avoid ADP-mediated platelet
activation and aggregation.
The benefit of ASA and P2Y12 antagonists in
ACS patients has been shown in several large
clinical studies [7]. However, the risk of further
thrombotic events remains high [8]. An analysis
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of the Global Registry of Acute Coronary Events
(GRACE) registry demonstrated 5-year mortality
rates in ACS patients under ASA and clopidogrel
treatment of 19%, 22%, and 17% in patients
with ST-elevation MI (STEMI), non-STEMI
(NSTEMI), and unstable angina (UA),
respectively [9]. The underlying phenomenon
for this observation might be related to
alternative platelet activation pathways, such
as those mediated by thrombin [8].
Clinical trials have demonstrated that even a
double antiplatelet therapy with ASA and
clopidogrel is insufficient in about one-third of
all treated patients resulting in recurrent
atherothrombotic events [10, 11].
Several clinical trials were designed to
compare treatment regimens of clopidogrel
to prasugrel and ticagrelor, which are known
to more effectively inhibit P2Y12 mediated
platelet aggregation [12, 13]. In the trial to
assess Improvement in Therapeutic Outcomes
by optimizing platelet inhibition with prasugrel
(TRITON-TIMI 38), prasugrel had superior
efficacy compared with clopidogrel [12]. The
composite endpoint of death from
cardiovascular causes, nonfatal MI, or nonfatal
stroke was 9.9% for prasugrel compared with
12.1% for clopidogrel. However, the rate of
thrombolysis in MI (TIMI) major bleeding was
elevated in patients receiving prasugrel
compared with patients receiving clopidogrel
(2.4% vs. 1.8%, respectively) [12]. In the
PLATelet inhibition and patient Outcomes
trial (PLATO), ticagrelor also demonstrated
superior efficacy compared with clopidogrel as
only 9.0% of patients experienced the primary
endpoint of cardiovascular death, MI, or stroke
compared with 10.7% of patients taking
clopidogrel [13]. Yet, similar to prasugrel, an
increase in the rate of bleeding was observed
with ticagrelor compared with clopidogrel [13].
Taken together, prasugrel and ticagrelor
represent improved treatment options and
reduce atherothrombosis. Nevertheless,
inhibition of other pathways may provide a
further opportunity to avoid ischemic events.
PROTEASE-ACTIVATED RECEPTOR
INHIBITORS
Targeting alternative pathways, which are not
affected by ASA or P2Y12 antagonists, is one
potential way to improve the treatment
options. Protease-activated receptors (PAR-1,
PAR-2, PAR-3, and PAR-4) are G-protein-
coupled receptors expressed on platelets and
other cells that are not involved in platelet
activation (e.g., neurons, myocytes, fibroblasts,
and endothelial cells) [8, 14]. Thrombin has the
highest affinity for PAR-1, but also activates
PAR-3 and PAR-4, whereas PAR-2 is activated by
trypsin and other proteases, but not by
thrombin. Only PAR-1 and PAR-4 are
expressed on platelets.
The principle thrombin receptor, PAR-1,
mediates platelet activation at subnanomolar
concentrations, whereas the other thrombin
receptor, PAR-4, requires higher thrombin
concentrations for activation [14]. The
inhibition of PAR-1 is a new approach in
antiplatelet strategies. Mechanistically, PAR-1
activation is achieved when thrombin
proteolytically cleaves a part of the
extracellular loop of the receptor. The newly
exposed N-terminus acts as a tethered ligand at
a transmembrane loop of the receptor [2]. The
effects of PAR-1 activation in endothelial and
vascular smooth muscle cells (SMCs) are not
fully established and are still controversial
[15–17]. On platelets it has been shown
that PAR-1 activation mediates calcium
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mobilization, platelet shape change, and
protein kinase C (PKC) activation finally
resulting in activation of the platelet GPIIb/
IIIa receptor [15, 16, 18]. Additionally, PAR-1
activation initiates intracellular signaling
pathways that stimulate platelet procoagulant
activities leading to enhanced thrombin
formation [19].
Several preclinical studies have indicated
that PAR-1 might be involved mainly in
pathological thromboembolic complications
and might not be essential for physiological
hemostasis [18–23]. Therefore, it was suggested
PAR-1 inhibition may provide beneficial
antithrombotic effects without inducing
bleeding complications and thus might be a
powerful alternative in antiplatelet treatment.
This review provides an overview of the two
PAR-1 antagonists in the most advanced stages
of development: vorapaxar [SCH530349; Merck
& Co., Whitehouse Station, NJ, USA (following
its merger with Schering-Plough)] and atopaxar
(E5555; Eisai, Tokyo, Japan).
Atopaxar (E5555)
Atopaxar is a low molecular weight (608 g/mol)
reversible PAR-1 antagonist. It is metabolized by
hepatic cytochrome CYP3A4 and eliminated
through the gastrointestinal tract [24]. In
preclinical studies, atopaxar demonstrated
inhibition of thrombin receptor-activating
peptides (TRAP)- and thrombin-induced
platelet aggregation [25, 26]. Furthermore,
atopaxar inhibited multiple other platelet
activity biomarkers in plasma samples from
healthy volunteers and patients with CAD
[27]. A study evaluated the inhibitory effect of
atopaxar on TRAP-induced platelet aggregation
from healthy volunteers (ASA naive) and
patients (n = 10 per group) with CAD who had
been treated with ASA (81 mg/day) alone or
combined with clopidogrel (75 mg/day) [27]. In
plasma samples from healthy volunteers and
patients, all concentrations of atopaxar
significantly, and almost completely, inhibited
TRAP-induced platelet aggregation compared
with a vehicle control.
Phase I Studies
The pharmacodynamics and safety properties of
atopaxar were evaluated in two studies. In a
randomized, double-blind, placebo-controlled,
dose-ascending study, 40 healthy volunteers
were randomized to receive 20, 50, 100, 200,
or 400 mg atopaxar [28]. The 24 volunteers were
randomized to three groups receiving 50, 100,
or 200 mg atopaxar or placebo for 10 days. It
was found that thrombin-induced platelet
aggregation was inhibited in a dose-dependent
manner, achieving the maximum effect 6 h
after onset. Repeated administration inhibited
thrombin-induced platelet aggregation almost
completely, even 24 h after the last
administration. At 7 days after the last
medication, platelet function had returned to
normal. Coagulation and bleeding times were
not influenced demonstrating the specific effect
of atopaxar [28].
At the time of publication, atopaxar had
undergone phase II evaluation in a series of
clinical trials cumulatively entitled Lesson from
Antagonizing the Cellular Effect of Thrombin
(LANCELOT) Trial that were undertaken in
populations of patients with CAD and ACS
in Japanese centers (NCT00540670 and
NCT00619164) as well as in centers outside
of Japan (NCT00312052 and NCT00548587)
[29–31].
Phase II Studies
To assess the safety of atopaxar, the Japanese
Lessons from Antagonizing the Cellular Effect
of Thrombin (J-LANCELOT) Trial [29]
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consisting of two multicenter, randomized,
double-blind, placebo-controlled phase II
studies in Japanese patients with ACS or high-
risk artery disease was conducted. In this trial
241 patients with NSTEMI or UA were
randomized to 50, 100, or 200 mg atopaxar for
12 weeks including a 400 mg loading dose
compared to placebo and placebo loading dose
[29].
In the CAD study, 263 patients were
randomized to receive the same doses of
atopaxar as in the ACS study. In contrast, they
did not receive a loading dose and were treated
for 24 weeks [29]. The primary safety endpoint
was the incidence of bleeding events
adjudicated according to the Clopidogrel in
Unstable Angina to Prevent Recurrent Events
CURE [32] and TIMI [33] definitions. The
secondary endpoint was the incidence of
major cardiovascular adverse events (MACE),
defined as cardiovascular death, MI, stroke, or
recurrent ischemia. Compared to placebo TIMI
minor bleeding was not increased in atopaxar
treated patients [ACS: 6.6% placebo vs. 5.0%
atopaxar (all dose groups); CAD: 1.5% placebo
vs. 1.5% atopaxar (all dose groups)] without the
occurrence of any TIMI major bleeding [29]. A
numerical increase in any TIMI bleeding with
the dose of 200 mg atopaxar was observed (ACS:
16.4% placebo vs. 23.0% atopaxar, P = 0.398;
CAD: 4.5% placebo vs. 13.2% atopaxar,
P = 0.081) [29]. The rate of MACE in the
combined atopaxar groups was not different
from placebo [ACS: 6.6% placebo vs. 5.0%
atopaxar (all dose groups), P = 0.73; CAD:
4.5% placebo vs. 1.0% atopaxar (all dose
groups), P = 0.066] [29]. TRAP-induced platelet
aggregation assessed in 42 ACS patients and
80 CAD patients showed inhibition by 20–60%
with 50 mg atopaxar and by 90% with 100 and
200 mg atopaxar in agreement with the results
of phase I studies [28, 29]. The most common
adverse event (AE) was hepatic function
disorder [ACS: 11.5% placebo vs. 23.3%
atopaxar (all dose groups), P = 0.064; CAD:
1.5% placebo vs. 10.2% atopaxar (all dose
groups), P = 0.032] [29]. In detail, in the ACS
patients hepatic function disorder was seen in
9.3%, 29.2%, and 29.5% in the 50, 100, and
200 mg atopaxar groups, respectively (100 mg
atopaxar vs. placebo, P = 0.015; 200 mg
atopaxar vs. placebo, P = 0.023). The rate of
hepatic function disorder in CAD patients was
lower. It was observed in 3.2%, 7.6%, and 19.1%
in the 50, 100, and 200 mg atopaxar groups,
respectively (200 mg atopaxar vs. placebo,
P = 0.001). Remarkably, a prolongation of QTc
in the 100 mg (P = 0.015) and 200 mg
(P = 0.037) groups in comparison with the
placebo group was also observed.
Based on the same study design
LANCELOT ACS and LANCELOT CAD studies
have recently been completed to evaluate the
safety of atopaxar outside of Japan in 603 and 720
patients, respectively [30, 31]. Although no
difference in any TIMI bleeding was observed in
LANCELOT ACS [ACS: 10.1% placebo vs. 9.3%
atopaxar (all dose groups), P = 0.77], a trend
towards increased TIMI bleeding in the atopaxar
groups was seen in LANCELOT CAD [CAD: 6.8%
placebo vs. 10.3% atopaxar (all dose groups),
P = 0.17]. Differences in bleeding rates reached
significant levels when analyzed according to the
CURE criteria [CAD: 0.6% placebo vs. 3.9%
atopaxar (all dose groups), P = 0.03]. TRAP-
induced platelet aggregation was inhibited 74%
at 1–3 h up to 92% at 3–6 h after loading dose
corresponding to the results of J-LANCELOT and
results of phase I studies [28, 29]. Similar to the
results from the J-LANCELOT trial, a dose-
dependent hepatic enzyme elevation and a
prolongation of the QTc interval at higher
doses were seen. In LANCELOT ACS atopaxar
significantly reduced ischemia on continuous
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electrocardiography (ECG) monitoring at 48 h
compared with placebo [relative risk (RR) 0.67,
P = 0.02] defined as horizontal or down-sloping
ST-segment depression C0.1 mV or upward ST-
segment elevation C0.1 mV [30]. The trial was
not powered for differences in ischemic clinical
endpoints.
The combined results of the phase II clinical
trials would have been sufficiently positive to
start phase III trials. However, the numerically
greater incidence in safety endpoints and AE,
such as QTc prolongation and liver enzyme
elevation, as well as the lack of a convincing
dose-related trend for safety and efficacy of
atopaxar, limit the encouraging results of these
clinical trials. Currently, the development of
atopaxar by Eisai is discontinued.
Vorapaxar (SCH530349)
Vorapaxar is an oral, low-molecular weight
(492.58 g/mol), high-affinity, competitive
PAR-1 antagonist, which has been shown in
preclinical studies to inhibit thrombin and
TRAP platelet aggregation without increased
bleeding complications [34, 35]. In a phase II
trial, vorapaxar administered in addition to
standard ASA and clopidogrel to ACS patients
was not associated with increased bleeding risks
and was well tolerated [36]. The rate of AEs was
comparable to the rate of AEs with standard
therapy alone. Based on these results, two large,
randomized, phase III trials [Thrombin Receptor
Antagonist for Clinical Event Reduction in ACS
(TRA-CER) and Thrombin Receptor Antagonist
in Secondary Prevention of atherothrombotic
ischemic events (TRA-2P)] were initiated to
evaluate the safety and efficacy of vorapaxar in
combination with the standard-of-care therapy
in patients who had NSTE-ACS or established
atherosclerosis, respectively [37, 38]. An
overview of the results is given in Table 1.
TRA-CER
Thrombin Receptor Antagonist for Clinical
Event Reduction in ACS was designed as a
multinational, double-blind, randomized trial
to compare vorapaxar (2.5 mg per day for at
least 1 year) with placebo in 12,944 ACS
patients that did not show any ST-segment
elevations [37]. The primary endpoint was a
composite of cardiovascular death, MI, stroke,
recurrent ischemia with rehospitalization, or
urgent coronary revascularization. After a
median follow-up time of 502 days, no
significant difference in the primary endpoint
was observed (18.5% vs. 19.9%; hazard ratio
[HR] 0.92; 95% confidence interval [CI]
0.85–1.01; P = 0.07), but it was found that
vorapaxar-treated patients had enhanced
bleeding complications in comparison to
placebo. Moderate and severe bleeding
according to the Global Utilization of
Streptokinase and t-PA for Occluded Coronary
Arteries (GUSTO) definition [39] were 7.2% in
the vorapaxar group and 5.2% in the placebo
group (HR 1.35; 95% CI 1.16–1.58; P\0.001).
According to TIMI bleeding criteria [40], major
or minor bleeding occurred in 6.5% of the cases
in the vorapaxar group compared to 4.0% in the
placebo group (HR 1.56; 95% CI 1.32–1.85;
P\0.001). Additionally, an increase in
intracranial hemorrhage (ICH) in the
vorapaxar group (1.1% vs. 0.2%; HR 3.39; 95%
CI 1.78–6.45; P\0.001) was observed. Due
to these elevated bleeding rates, the data
and safety monitoring board (DSMB) of the
TRA-CER trial recommended after a safety
review on January 8, 2011 that the trial
should stopped rather than continued until
June 4, 2011 as planned. The protocol-defined
target number of primary efficacy endpoints
had been reached. Following the
recommendation of the DSMB, the study drug
was discontinued and the follow-up in the
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TRA-CER trial was terminated. In addition, the
DSMB recommended the termination of the
study drug in patients with a history of stroke
in the TRA-2P trial.
The key secondary endpoint (a composite of
death from cardiovascular causes, MI, or stroke)
occurred in 822 patients in the vorapaxar group
and 910 patients in the placebo group (14.7%
vs. 16.4%, respectively; HR 0.89, 95% CI
0.81–0.98; P = 0.02) [37]. The reduction in the
rate of MI was the main effect observed in the
vorapaxar group, compared with the placebo
group (11.1% vs. 12.5%; HR 0.88, 95% CI
0.79–0.98; P = 0.02) [37]. However, the rates of
death from any cause did not vary significantly
(6.5% vs. 6.1%; HR 1.05, 95% CI 0.90–1.23;
P = 0.52).
The authors conclude that in patients with
ACS, the addition of vorapaxar to standard
therapy did not significantly reduce the primary
composite endpoint but significantly increased
the risk of major bleeding, including ICH [37].
TRA 2P-TIMI50
The TRA 2P-TIMI50 trial evaluated the effect
of vorapaxar on patients with a history of
atherosclerosis, defined as a spontaneous MI or
ischemic stroke within the previous 2 weeks
to 12 months or peripheral arterial disease
associated with a history of intermittent
claudication in conjunction with either an
ankle brachial index of less than 0.85 or
previous revascularization for limb ischemia
[38, 41]. In this study 13,225 patients were
randomly assigned to receive vorapaxar (2.5 mg
daily) and 13,224 patients to receive placebo.
The median follow-up time was 30 months. As
mentioned earlier, the DSMB recommended
discontinuing the study treatment in patients
with a history of stroke due to an increased risk
of ICH in January 2011. Initially, the primary
efficacy endpoint consisted of the composite of
cardiovascular death, MI, stroke, or recurrent
ischemia leading to urgent coronary
revascularization. The secondary endpoint was
defined as the composite of cardiovascular
death, MI, or stroke. However, due to the
results of the TRA-CER trial, the steering
committee amended the main data-analysis
plan to reorder the hierarchy of efficacy
analyses, defining as the primary endpoint the
composite of cardiovascular death, MI, or
stroke. At 3 years, the primary endpoint had
occurred less frequently in patients receiving
vorapaxar compared to patients receiving
placebo (9.3% vs. 10.5%; HR 0.87; 95% CI
0.80–0.94; P\0.001). The secondary endpoint
occurred in 11.2% of the patients in the
vorapaxar group and 12.4% in the placebo
group (HR 0.88; 95% CI 0.82–0.95; P = 0.001).
In contrast, bleeding complications were
increased in patients receiving vorapaxar.
Moderate and severe GUSTO bleedings
occurred in 4.2% in the vorapaxar group and
in 2.5% in the placebo group (HR 1.66; 95% CI
1.43–1.93; P\0.001) [38]. ICH occurred in
significantly more patients in the vorapaxar
group than in the placebo group (1.0% vs. 0.5%;
HR 1.94; 95% CI 1.39–2.70; P\0.001). Whereas
no significant difference was observed in net
clinical outcome, defined as the composite of
cardiovascular death, MI, stroke, or GUSTO
moderate or severe bleeding (11.7% in the
vorapaxar group and 12.1% in the placebo
group; HR 0.97; 95% CI 0.90–1.04; P = 0.40)
[38].
Taking these data together, looking at the
total patient populations vorapaxar reduces the
rate of cardiovascular death, MI, or stroke in
patients with a history of atherothrombosis
who were receiving standard therapy at the
cost of increased bleeding, including ICH [38].
To identify patients in which the benefit-risk
ratio can be optimized prespecified subanalysis
64 Cardiol Ther (2013) 2:57–68
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were performed. In the subgroup of patients
with a qualifying MI within the previous
2 weeks to 12 months (8,898 patients receiving
vorapaxar and 8,881 receiving placebo) the
primary endpoint occurred less frequently in
vorapaxar-treated patients than in placebo-
treated patients (8.1% vs. 9.7% in the placebo
group; HR 0.80, 95% CI 0.72–0.89; P\0.0001)
[42]. Conversely, GUSTO moderate or severe
bleeding occurred more frequently in the
vorapaxar group than in the placebo group
(3.4% vs. 2.1%, respectively; HR 1.61, 95% CI
1.31–1.97; P\0.0001). Moreover, a numerical
increase in ICH in the vorapaxar group
compared to the placebo group was observed
(0.6% vs. 0.4%, respectively; P = 0.076)
[42].
In another subanalysis including the 3,787
patients with peripheral arterial disease,
hospitalizations for acute limb ischemia (2.3%
vs. 3.9%; HR 0.58; 95% CI 0.39–0.86; P = 0.006)
and peripheral arterial revascularization (18.4%
vs. 22.2%; HR 0.84; 95% CI 0.73–0.97;
P = 0.017) were lower in the vorapaxar group.
Nonetheless, moderate or severe bleeding was
increased with vorapaxar (7.4% vs. 4.5%; HR
1.62; 95% CI 1.21–2.18; P = 0.001) including
ICH (0.9% vs. 0.4%; HR 2.03; 95% CI 0.82–5.02;
P = 0.13) [43].
Taken together, vorapaxar in addition
to standard treatment may be beneficial in
the secondary prevention of patients with
established atherosclerosis who have a history
of MI [44]. For patients with peripheral arterial
disease, vorapaxar might be an option to
reduce limb ischemia at the risk of increased
bleeding.
New Experimental Par-1 Inhibitors
There are several new experimental PAR-1
inhibitors with different pharmacodynamic
profiles and slightly different mechanisms of
action, which are currently in preclinical trials
[45]. To date, PZ-128 is the furthest along in
preclinical trials [46].
CURRENT OPINION
Although antiplatelet agents such as ASA and
P2Y12 antagonists are well established for
patients with atherothrombotic complications,
the risk of thrombotic and ischemic events still
remains considerably high. A suboptimal
inhibition of platelet aggregation might
explain the residual mortality and underscores
the need for novel antiplatelet agents to
optimize the balance between antithrombotic
efficacy and bleeding risk. Inhibition of
additional pathways not affected by ASA or
P2Y12 antagonists could offer more effective
inhibition of platelet aggregation and avoid
platelet-mediated thrombosis. A promising
candidate is the PAR-1 receptor, which is
activated by thrombin and represents a
validated therapeutic target mediating
thrombosis without being critical for
hemostasis in preclinical models. Vorapaxar
and atopaxar are new PAR-1 receptor
antagonists tested in clinical trials.
Atopaxar, although well tolerated in initial
clinical trials, was accompanied by a higher
incidence of safety endpoints, such as QTc
prolongations. Therefore, in the presence of a
lack of convincing dose-related trend for
efficacy its further clinical development is
currently halted.
Vorapaxar has passed a clinical phase III
program and demonstrated in the TRA-CER
study that triple antiplatelet therapy including
aspirin, clopidogrel, and vorapaxar is
accompanied by increased bleeding rates
without a significant benefit in terms of
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ischemic events. However, specific subgroups,
such as patients with previous MI or peripheral
artery disease, may still take advantage of
additional inhibition of the PAR-1 receptor.
In a recently published meta-analysis on
PAR-1 antagonists, Chatterjee et al. [47] found
that PAR-1 antagonists in addition to standard
medical therapy may reduce the risk of
cardiovascular mortality and recurrent MI but
also enhances bleeding.
Until now no clinical approval has been
granted for PAR-1 antagonists. The future of this
novel class of antithrombotic drugs will depend
on the identification of patient groups in which
the risk–benefit ratio is favorable. Moreover, it is
not known how PAR-1 blockers interfere with
the new P2Y12 antagonists, prasugrel and
ticagrelor.
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